GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » EBIT

MusclePharm (MusclePharm) EBIT : $-16.48 Mil (TTM As of Mar. 2022)


View and export this data going back to 2008. Start your Free Trial

What is MusclePharm EBIT?

MusclePharm's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2022 was $-5.66 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2022 was $-16.48 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MusclePharm's annualized ROC % for the quarter that ended in Mar. 2022 was -44.70%. MusclePharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -13,055.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MusclePharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -74.39%.


MusclePharm EBIT Historical Data

The historical data trend for MusclePharm's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MusclePharm EBIT Chart

MusclePharm Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.57 -6.86 -15.09 4.86 -10.21

MusclePharm Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 -1.60 -3.22 -5.99 -5.66

Competitive Comparison of MusclePharm's EBIT

For the Packaged Foods subindustry, MusclePharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MusclePharm's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, MusclePharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MusclePharm's EV-to-EBIT falls into.



MusclePharm EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MusclePharm  (OTCPK:MSLPQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MusclePharm's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:

ROC % (Q: Mar. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Mar. 2022 ))/ count )
=-9.92 * ( 1 - 0% )/( (19.5 + 24.881)/ 2 )
=-9.92/22.1905
=-44.70 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

MusclePharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2021  Q: Mar. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.652/( ( (0.208 + max(-14.178, 0)) + (0.139 + max(-14.227, 0)) )/ 2 )
=-22.652/( ( 0.208 + 0.139 )/ 2 )
=-22.652/0.1735
=-13,055.91 %

where Working Capital is:

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.388 + 1.83 + 1.526) - (21.818 + 0 + 2.104)
=-14.178

Working Capital(Q: Mar. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.277 + 0.975 + 1.052) - (23.429 + 0 + 2.102)
=-14.227

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MusclePharm's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2022 )
=-16.475/22.147
=-74.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MusclePharm EBIT Related Terms

Thank you for viewing the detailed overview of MusclePharm's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MusclePharm (MusclePharm) Business Description

Traded in Other Exchanges
N/A
Address
6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118
MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.
Executives
Eric Chin officer: Chief Accounting Officer 1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr director BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi officer: President & CFO 6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller director 4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc. 10 percent owner 1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc 10 percent owner C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney 10 percent owner 4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc 10 percent owner 265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell 10 percent owner 8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond director 10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123